Innate Pharma S.A. (IPHA) shares are rising more than 29 percent on Thursday morning trade. The company said AstraZeneca will make two oral presentations on COAST phase 2 trial of Innate's monalizumab in combination with durvalumab. Further, Innate will present pre-clinical data from multi specific NK cell engager platform ANKET.

Create Account

Dark

chart

exchange

Check out our Level2View

Innate Pharma S.A. (IPHA) shares are rising more than 29 percent on Thursday morning trade. The company said AstraZeneca will make two oral presentations on COAST phase 2 trial of Innate's monalizumab in combination with durvalumab. Further, Innate will present pre-clinical data from multi specific NK cell engager platform ANKET.

RTTNews | Sep 2, 2021 10:49AM EDT

10:48 Thursday, September 2, 2021 (RTTNews.com) - Innate Pharma S.A. (IPHA) shares are rising more than 29 percent on Thursday morning trade. The company said AstraZeneca will make two oral presentations on COAST phase 2 trial of Innate's monalizumab in combination with durvalumab. Further, Innate will present pre-clinical data from multi specific NK cell engager platform ANKET.

The presentation at ESMO 2021 Virtual Congress on Monalizumab will be on September 17 and the ANKET presentation will be on September 18.

Currently, shares are at $4.58, up 29.17 percent from the previous close of $3.55.

Read the original article on RTTNews ( https://www.rttnews.com/3222975/innate-pharma-rallies-in-morning-trade.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved